Alnylam Net Debt from 2010 to 2025

ALNY Stock

USD 283.34 29.79 11.75%

Alnylam Pharmaceuticals Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about -133.5 M in 2025. Net Debt is the total debt of Alnylam Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2003-12-31

Previous Quarter

201.9 M

Current Value

329.6 M

Quarterly Volatility

506.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Alnylam Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alnylam Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.5 M, Interest Expense of 149 M or Other Operating Expenses of 2.5 B, as well as many indicators such as Price To Sales Ratio of 12.79, Dividend Yield of 0.0 or PTB Ratio of 474. Alnylam financial statements analysis is a perfect complement when working with Alnylam Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Alnylam Pharmaceuticals Correlation against competitors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Latest Alnylam Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of Alnylam Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Alnylam Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alnylam Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

Alnylam Net Debt Regression Statistics

	Arithmetic Mean	(86,265,166)
	Geometric Mean	171,078,034
	Coefficient Of Variation	(773.06)
	Mean Deviation	383,563,561
	Median	(53,169,000)
	Standard Deviation	666,883,434
	Sample Variance	444733.5T
	Range	3.2B
	R-Value	0.39
	Mean Square Error	405533.9T
	R-Squared	0.15
	Significance	0.14
	Slope	54,056,836
	Total Sum of Squares	6671002.7T

Alnylam Net Debt History

	2025	-133.5 M
	2024	-127.1 M
	2023	1.9 B
	2022	453.9 M
	2021	177.6 M
	2020	24.6 M
	2019	-243.4 M

Other Fundumenentals of Alnylam Pharmaceuticals

Net Debt To E B I T D A

Alnylam Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Intangible Assets	Net Receivables	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.15	0.39	-0.98	0.89	0.97	0.93	0.99	0.96	0.26	0.88	0.33	0.85	0.89	0.83	-0.25	0.99	-0.63	-0.6	0.82	-0.85	-0.89	0.57	0.94
Total Stockholder Equity	-0.15		-0.63	0.29	-0.15	-0.15	-0.49	-0.13	-0.19	0.33	-0.55	0.18	-0.39	-0.5	0.19	0.99	-0.08	-0.45	0.14	-0.63	-0.1	0.39	-0.61	-0.46
Net Debt	0.39	-0.63		-0.52	0.32	0.48	0.57	0.35	0.46	0.09	0.58	0.23	0.47	0.48	0.29	-0.59	0.36	0.09	-0.42	0.52	-0.35	-0.63	0.45	0.54
Retained Earnings	-0.98	0.29	-0.52		-0.91	-0.96	-0.96	-0.96	-0.98	-0.18	-0.94	-0.36	-0.89	-0.92	-0.81	0.38	-0.97	0.55	0.64	-0.88	0.85	0.95	-0.58	-0.96
Accounts Payable	0.89	-0.15	0.32	-0.91		0.87	0.84	0.88	0.92	0.1	0.84	0.32	0.76	0.8	0.78	-0.25	0.93	-0.6	-0.51	0.77	-0.79	-0.85	0.42	0.84
Short Term Investments	0.97	-0.15	0.48	-0.96	0.87		0.91	0.95	0.97	0.3	0.85	0.35	0.84	0.86	0.8	-0.24	0.97	-0.55	-0.71	0.78	-0.91	-0.87	0.54	0.91
Total Liab	0.93	-0.49	0.57	-0.96	0.84	0.91		0.92	0.91	0.11	0.97	0.22	0.89	0.96	0.66	-0.58	0.89	-0.39	-0.58	0.95	-0.72	-0.93	0.72	0.99
Total Current Assets	0.99	-0.13	0.35	-0.96	0.88	0.95	0.92		0.93	0.19	0.89	0.29	0.85	0.9	0.82	-0.24	0.97	-0.66	-0.56	0.84	-0.83	-0.86	0.6	0.92
Property Plant Equipment	0.96	-0.19	0.46	-0.98	0.92	0.97	0.91	0.93		0.3	0.86	0.46	0.87	0.85	0.8	-0.28	0.98	-0.53	-0.72	0.8	-0.91	-0.93	0.44	0.93
Current Deferred Revenue	0.26	0.33	0.09	-0.18	0.1	0.3	0.11	0.19	0.3		-0.04	0.62	0.01	-0.06	0.38	0.33	0.25	-0.21	-0.27	-0.11	-0.32	-0.12	-0.03	0.19
Long Term Debt	0.88	-0.55	0.58	-0.94	0.84	0.85	0.97	0.89	0.86	-0.04		0.21	0.87	0.96	0.62	-0.63	0.85	-0.36	-0.51	0.98	-0.65	-0.9	0.75	0.96
Short Term Debt	0.33	0.18	0.23	-0.36	0.32	0.35	0.22	0.29	0.46	0.62	0.21		0.27	0.13	0.43	0.16	0.4	-0.27	-0.44	0.13	-0.49	-0.37	-0.13	0.32
Intangible Assets	0.85	-0.39	0.47	-0.89	0.76	0.84	0.89	0.85	0.87	0.01	0.87	0.27		0.94	0.57	-0.49	0.85	-0.37	-0.59	0.87	-0.71	-0.86	0.49	0.91
Net Receivables	0.89	-0.5	0.48	-0.92	0.8	0.86	0.96	0.9	0.85	-0.06	0.96	0.13	0.94		0.57	-0.6	0.85	-0.38	-0.5	0.97	-0.65	-0.85	0.72	0.95
Common Stock	0.83	0.19	0.29	-0.81	0.78	0.8	0.66	0.82	0.8	0.38	0.62	0.43	0.57	0.57		0.11	0.85	-0.81	-0.47	0.51	-0.81	-0.73	0.31	0.66
Net Tangible Assets	-0.25	0.99	-0.59	0.38	-0.25	-0.24	-0.58	-0.24	-0.28	0.33	-0.63	0.16	-0.49	-0.6	0.11		-0.18	-0.35	0.17	-0.71	-0.02	0.46	-0.65	-0.55
Capital Surpluse	0.99	-0.08	0.36	-0.97	0.93	0.97	0.89	0.97	0.98	0.25	0.85	0.4	0.85	0.85	0.85	-0.18		-0.64	-0.65	0.78	-0.9	-0.9	0.45	0.91
Deferred Long Term Liab	-0.63	-0.45	0.09	0.55	-0.6	-0.55	-0.39	-0.66	-0.53	-0.21	-0.36	-0.27	-0.37	-0.38	-0.81	-0.35	-0.64		0.12	-0.28	0.56	0.42	-0.12	-0.38
Long Term Investments	-0.6	0.14	-0.42	0.64	-0.51	-0.71	-0.58	-0.56	-0.72	-0.27	-0.51	-0.44	-0.59	-0.5	-0.47	0.17	-0.65	0.12		-0.45	0.85	0.68	-0.15	-0.6
Long Term Debt Total	0.82	-0.63	0.52	-0.88	0.77	0.78	0.95	0.84	0.8	-0.11	0.98	0.13	0.87	0.97	0.51	-0.71	0.78	-0.28	-0.45		-0.55	-0.84	0.78	0.94
Short Long Term Debt	-0.85	-0.1	-0.35	0.85	-0.79	-0.91	-0.72	-0.83	-0.91	-0.32	-0.65	-0.49	-0.71	-0.65	-0.81	-0.02	-0.9	0.56	0.85	-0.55		0.81	-0.21	-0.73
Net Invested Capital	-0.89	0.39	-0.63	0.95	-0.85	-0.87	-0.93	-0.86	-0.93	-0.12	-0.9	-0.37	-0.86	-0.85	-0.73	0.46	-0.9	0.42	0.68	-0.84	0.81		-0.46	-0.92
Net Working Capital	0.57	-0.61	0.45	-0.58	0.42	0.54	0.72	0.6	0.44	-0.03	0.75	-0.13	0.49	0.72	0.31	-0.65	0.45	-0.12	-0.15	0.78	-0.21	-0.46		0.69
Capital Stock	0.94	-0.46	0.54	-0.96	0.84	0.91	0.99	0.92	0.93	0.19	0.96	0.32	0.91	0.95	0.66	-0.55	0.91	-0.38	-0.6	0.94	-0.73	-0.92	0.69

Click cells to compare fundamentals

About Alnylam Pharmaceuticals Financial Statements

Alnylam Pharmaceuticals investors use historical fundamental indicators, such as Alnylam Pharmaceuticals' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Alnylam Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-127.1 M	-133.5 M
Net Debt To EBITDA	(6.54)	(6.21)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Net Debt from 2010 to 2025

Latest Alnylam Pharmaceuticals' Net Debt Growth Pattern

Alnylam Net Debt Regression Statistics

Alnylam Net Debt History

Other Fundumenentals of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Net Debt component correlations

About Alnylam Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY